New Publication: Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

/0 Comments/in /by
We are excited to report the publication of our manuscript Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration with BMJ Open. View the Article online with BMJ by clicking here Download a PDF copy directly by clicking (more…)

CanREValue Interim Policy Report Open for Feedback

/0 Comments/in , , /by
The CanREValue Collaboration is pleased to open the feedback consultation period for our Policy Working Groups: Developing a framework for incorporating real-world evidence into drug funding decisions: CanREValue Collaboration Policy Working Groups Interim Report 2019. View the Policy Working Groups Report here View the Report Appendix here Feedback Form Stakeholder input is (more…)

CanREValue Interim Data Report Open for Feedback

/0 Comments/in , , /by
The CanREValue Collaboration is pleased to open the feedback consultation period for our first Data Working Group Interim Report: Mapping Canadian Provincial Data Assets to Conduct Real-World Studies on Cancer Drugs. View the Interim Data Working Group Report here View the Report Appendix here Feedback Form We welcome any stakeholder (more…)

Engagement Webinar Recording & Slides Now Available

/0 Comments/in /by
We have now uploaded a copy of the slides and a full recording of our Stakeholder Engagement Webinar which was held on Wednesday November 6th 2019. View a copy of the slide deck here Listen to & watch the recorded webinar here Please feel free to share these links with (more…)

Article: Is There Evidence in Real-World Evidence?

/0 Comments/in /by
“Evidence from real-world practice and utilization—outside of clinical trials—is seen to tailor healthcare decision-making more closely to the characteristics of individual patients, and thus as a step towards making healthcare more personalized and effective.” A new overview on the potential uses and benefits of RWE has been published by PharmExec.com, authored (more…)

Welcome to the CanREValue Website

/0 Comments/in /by
CanREValue is happy to announce our initial website is now live! Still under construction, we expect the Working Group and Resources sections to be populated in early 2019, and we will also upload copies of presentations & abstracts on the Knowledge Translation page. Should you have any questions about the (more…)

FDA’s RWE Framework

/0 Comments/in /by
Earlier in December the FDA released a new framework outlining how they will use Real World Evidence (RWE) and Real World Data (RWD) in decision making for new drugs and biologics.  Under the new framework, the FDA will use the following three criteria to evaluate RWE/RWD: 1. Whether the RWD are fit (more…)